New York, July 09, 2014 -- Moody's Investors Service commented that the agreement by Salix Pharmaceutical, Ltd. ("Salix") to merge with Cosmo Technologies Limited ("Cosmo Tech"), a subsidiary of Cosmo Pharmaceuticals S.p.A. (collectively "Cosmo") is credit-positive. The deal provides financial benefits and enhances Salix's business profile. There is currently no effect on Salix's existing ratings including the B1 Corporate Family Rating, the Ba1 senior secured rating and the B2 senior unsecured rating. The rating outlook is stable. Cosmo is unrated.

Vollständigen Artikel bei Moodys lesen